HK1220136A1 - 治疗b2-缓激肽受体介导的血管性水肿的方法 - Google Patents

治疗b2-缓激肽受体介导的血管性水肿的方法 Download PDF

Info

Publication number
HK1220136A1
HK1220136A1 HK16108272.4A HK16108272A HK1220136A1 HK 1220136 A1 HK1220136 A1 HK 1220136A1 HK 16108272 A HK16108272 A HK 16108272A HK 1220136 A1 HK1220136 A1 HK 1220136A1
Authority
HK
Hong Kong
Prior art keywords
receptor mediated
bradykinin receptor
treating
methods
mediated angioedema
Prior art date
Application number
HK16108272.4A
Other languages
English (en)
Chinese (zh)
Inventor
Leach Kevin
Wright Teresa
Felice Brian
Pfeifer Richard
Calias Pericles
Mccauley Thomas
Original Assignee
Shire Human Genetic Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies, Inc. filed Critical Shire Human Genetic Therapies, Inc.
Publication of HK1220136A1 publication Critical patent/HK1220136A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HK16108272.4A 2013-03-14 2014-03-12 治疗b2-缓激肽受体介导的血管性水肿的方法 HK1220136A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786126P 2013-03-14 2013-03-14
US61/786,126 2013-03-14
PCT/US2014/024540 WO2014159637A1 (en) 2013-03-14 2014-03-12 Methods of treating b2-bradykinin receptor mediated angioedema

Publications (1)

Publication Number Publication Date
HK1220136A1 true HK1220136A1 (zh) 2017-04-28

Family

ID=51625217

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108272.4A HK1220136A1 (zh) 2013-03-14 2014-03-12 治疗b2-缓激肽受体介导的血管性水肿的方法

Country Status (12)

Country Link
US (1) US20160030416A1 (https=)
EP (1) EP2968308A4 (https=)
JP (1) JP2016514141A (https=)
KR (1) KR20150127718A (https=)
CN (1) CN105228623A (https=)
AU (1) AU2014244592A1 (https=)
BR (1) BR112015022846A2 (https=)
CA (1) CA2904052A1 (https=)
HK (1) HK1220136A1 (https=)
MX (1) MX2015012650A (https=)
RU (1) RU2015138443A (https=)
WO (1) WO2014159637A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017325986B2 (en) * 2016-09-16 2023-12-14 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
WO2019101906A1 (en) 2017-11-24 2019-05-31 Pharvaris B.V. Novel bradykinin b2 receptor antagonists
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
UY38706A (es) * 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
UY38707A (es) * 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
US11401303B2 (en) 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
RS65427B1 (sr) 2021-08-05 2024-05-31 Pharvaris Gmbh Kompozicija na bazi lipida za oralnu primenu antagonista receptora bradikinina b2
EP4499100A1 (en) 2022-03-25 2025-02-05 Pharvaris GmbH Therapeutic uses of bradykinin b2-receptor antagonists
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
IL315699A (en) 2022-03-25 2024-11-01 Pharvaris Gmbh A solid composition comprising dissolved bradykinin B2 receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
KR20040011549A (ko) * 2001-06-22 2004-02-05 화이자 프로덕츠 인크. 저용해도 및(또는) 산-민감성 약물 및 중화된 산성중합체를 포함하는 제약 조성물
WO2003087090A2 (en) * 2002-04-10 2003-10-23 Ortho-Mcneil Pharmaceutical,Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
US20100068301A1 (en) * 2006-11-30 2010-03-18 Hutchinson John H Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
TWI407960B (zh) * 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
IT1391236B1 (it) * 2008-07-11 2011-12-01 St Luso Farm D'italia Spa Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso
EP2316820A1 (en) * 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
US20160030416A1 (en) 2016-02-04
EP2968308A1 (en) 2016-01-20
EP2968308A4 (en) 2016-08-24
BR112015022846A2 (pt) 2017-11-07
AU2014244592A1 (en) 2015-09-24
CA2904052A1 (en) 2014-10-02
KR20150127718A (ko) 2015-11-17
RU2015138443A3 (https=) 2018-03-15
CN105228623A (zh) 2016-01-06
WO2014159637A1 (en) 2014-10-02
JP2016514141A (ja) 2016-05-19
MX2015012650A (es) 2016-06-21
RU2015138443A (ru) 2017-04-20

Similar Documents

Publication Publication Date Title
HK1220136A1 (zh) 治疗b2-缓激肽受体介导的血管性水肿的方法
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
NZ732154A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3139935A4 (en) Therapeutic placental compositions, methods of making and methods of use
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
EP3153170A4 (en) Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
PL3388420T3 (pl) Związki chinolinowe, sposób ich wytwarzania i ich zastosowanie jako leku stanowiącego inhibitor transportera anionu kwasu moczowego
EP3337482A4 (en) TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS
EP3061452A4 (en) Use of icaritin in preparing medicament for preventing or treating hematocytopenia
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
HK1204928A1 (en) Inhibitors of the notch signalling pathway and secretion for use in medicine
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EP3113775A4 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
EP3513792A4 (en) USE OF MORPHINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE OPIOID RECEPTOR AGONIST
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP3277269A4 (en) Methods for prevention and treatment of cardiometabolic syndrome and compositions used therein
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
TN2016000497A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine